Clinical Trial Update: MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention [Phase 3]

View source ↗

Summary

Phase 3 trial update about using Midregional Proatrial Natriuretic Peptide to guide secondary stroke prevention in ischemic stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Midregional Proatrial Natriuretic Peptide (midregional proatrial natriuretic peptide)

Snippet

Sponsor: University of Zurich | Conditions: Stroke, Ischemic | Phase 3 | Status: UNKNOWN